Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed
December 12th 2023OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Read More
Dr. Landgren on the Use of Triplets Versus Quadruplets in Multiple Myeloma
March 26th 2018C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the superiority of 3-drug regimens and the next steps in the treatment of patients with multiple myeloma.
Read More
Dr. Landgren on Daratumumab Triplet in Relapsed Myeloma
January 19th 2017C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the triplet of daratumumab, bortezomib, and dexamethasone in the treatment of patients with relapsed myeloma.
Read More
Dr. Landgren on Questions After POLLUX and CASTOR Studies in Myeloma
January 6th 2017C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses unanswered questions following the results of the phase III POLLUX and CASTOR studies, which explored the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone, respectively.
Read More
Dr. Landgren Discusses MRD Detection for Multiple Myeloma
November 4th 2015C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.
Read More
Dr. Landgren on Combinations in Newly Diagnosed Myeloma
December 16th 2013C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.
Read More